Potential Differences in Psychedelic Actions Based on Biological Sex DOI Creative Commons

Sheida Shadani,

Kyna‐Anne Conn, Zane B. Andrews

и другие.

Endocrinology, Год журнала: 2024, Номер 165(8)

Опубликована: Июль 1, 2024

The resurgence of interest in psychedelics as treatments for psychiatric disorders necessitates a better understanding potential sex differences response to these substances. Sex biological variable (SABV) has been historically neglected medical research, posing limits our treatment efficacy. Human studies have provided insights into the efficacy across various diagnoses and aspects cognition, yet sex-specific effects remain unclear, making it difficult draw strong conclusions about sex-dependent psychedelic treatments. Compounding this further, animal used understand mechanisms predominantly use one present mixed neurobiological behavioral outcomes. Studies that do include both sexes often not investigate which may hinder translation findings clinic. In reviewing responses psychedelics, we will highlight direct interaction between estrogen (the most extensively studied steroid hormone) serotonin system (central mechanism action psychedelics), estrogen-serotonin interactions influence female participants. Estrogen influences neurotransmission by affecting its synthesis release, well modulating sensitivity responsiveness receptor subtypes brain. This could potentially females modifying their therapeutic menstrual cycles developmental stages. Investigating context research aid advancement outcomes, especially conditions with prevalence.

Язык: Английский

Psychedelics reopen the social reward learning critical period DOI Creative Commons

Romain Nardou,

Edward J. Sawyer, Young Jun Song

и другие.

Nature, Год журнала: 2023, Номер 618(7966), С. 790 - 798

Опубликована: Июнь 14, 2023

Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state consciousness 1,2 . These have been used for millennia in both spiritual and medicinal contexts, number recent clinical successes spurred renewed interest developing psychedelic therapies 3–9 Nevertheless, unifying mechanism that can account these shared phenomenological therapeutic properties remains unknown. Here we demonstrate mice the reopen social reward learning critical period is property across drugs. Notably, time course reopening proportional duration acute subjective effects reported humans. Furthermore, reinstate adulthood paralleled metaplastic restoration oxytocin-mediated long-term depression nucleus accumbens. Finally, identification differentially expressed genes ‘open state’ versus ‘closed provides evidence reorganization extracellular matrix common downstream underlying drug-mediated reopening. Together results important implications implementation psychedelics practice, as well design novel compounds treatment neuropsychiatric disease.

Язык: Английский

Процитировано

146
Accelerated TMS - moving quickly into the future of depression treatment DOI Creative Commons
Sanne J.H. van Rooij,

Amanda R. Arulpragasam,

William M. McDonald

и другие.

Neuropsychopharmacology, Год журнала: 2023, Номер 49(1), С. 128 - 137

Опубликована: Май 22, 2023

Abstract Accelerated TMS is an emerging application of Transcranial Magnetic Stimulation (TMS) aimed to reduce treatment length and improve response time. Extant literature generally shows similar efficacy safety profiles compared the FDA-cleared protocols for treat major depressive disorder (MDD), yet accelerated research remains at a very early stage in development. The few applied have not been standardized vary significantly across set core elements. In this review, we consider nine elements that include parameters (i.e., frequency inter-stimulation interval), cumulative exposure number days, sessions per day, pulses session), individualized target dose), brain state context concurrent treatments). Precisely which these critical what are most optimal MDD unclear. Other important considerations durability effect, as doses increase over time, possibility advantage functional neuronavigation, use biological readouts, accessibility patients need treatment. Overall, appears hold promise time achieve rapid reduction symptoms, but significant work be done. Rigorous clinical trials combining outcomes neuroscientific measures such electroencephalogram, magnetic resonance imaging e-field modeling needed define future MDD.

Язык: Английский

Процитировано

47
A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behavior DOI Creative Commons

Lingsha Cheng,

Haoqian Wu, Xiaoying Cai

и другие.

Cell Host & Microbe, Год журнала: 2024, Номер 32(2), С. 227 - 243.e6

Опубликована: Янв. 9, 2024

Язык: Английский

Процитировано

36
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? DOI Creative Commons

Mehdi Sekssaoui,

Joël Bockaert, Philippe Marin

и другие.

Neuropsychopharmacology, Год журнала: 2024, Номер 49(4), С. 747 - 756

Опубликована: Янв. 11, 2024

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment 30% patients and delayed clinical benefit that observed only after several weeks treatment. Increasing evidence indicates acute administration psychedelic agonists 5-HT

Язык: Английский

Процитировано

23
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile DOI Creative Commons
Friederike Holze, Nirmal Singh, Matthias E. Liechti

и другие.

Biological Psychiatry Cognitive Neuroscience and Neuroimaging, Год журнала: 2024, Номер 9(5), С. 472 - 489

Опубликована: Фев. 1, 2024

Psychedelic compounds, including psilocybin, LSD, DMT, and 5-MeO-DMT all of which are serotonin (5-HT) 2A receptor agonists being investigated as potential treatments. This review aims to summarize the current clinical research on these four compounds mescaline guide future research. Their mechanism/s action, pharmacokinetics, pharmacodynamics, efficacy, safety were reviewed. While evidence for therapeutic indications, with exception psilocybin depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. It remains therefore unclear whether different profiles contribute compounds. More needed differentiate order inform might be best uses.

Язык: Английский

Процитировано

20
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects DOI Creative Commons
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer

и другие.

Frontiers in Psychiatry, Год журнала: 2024, Номер 14

Опубликована: Янв. 8, 2024

There is growing scientific evidence for the therapeutic benefits of Amazonian plant-based psychedelic "ayahuasca" neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research clinical therapy environments. Formulations inspired by ayahuasca, which contain specific standardized active components, a potential remedy.

Язык: Английский

Процитировано

16
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity DOI
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk

и другие.

Headache The Journal of Head and Face Pain, Год журнала: 2024, Номер 64(1), С. 55 - 67

Опубликована: Янв. 1, 2024

Abstract Objective To evaluate the feasibility and prophylactic effect of psilocybin as well its effects on hypothalamic functional connectivity (FC) in patients with chronic cluster headache (CCH). Background CCH is an excruciating difficult‐to‐treat disorder incompletely understood pathophysiology, although dysfunction has been implicated. Psilocybin may have beneficial effects, but clinical evidence limited. Methods In this small open‐label trial, 10 were included maintained diaries for weeks. Patients received three doses peroral (0.14 mg/kg) first day weeks five, six, seven. The 4 served baseline last follow‐up. Hypothalamic FC was determined using magnetic resonance imaging before dose 1 week after dose. Results treatment tolerated. Attack frequency reduced by mean (standard deviation) 31% (31) from to follow‐up ( p FWER = 0.008). One patient experienced 21 complete remission. Changes hypothalamic–diencephalic correlated negatively a percent change attack 0.03, R −0.81), implicating neural pathway response. Conclusion Our results indicate that potential implicates hypothalamus possible Further studies are warranted.

Язык: Английский

Процитировано

16
Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice DOI

Xiangting Zhao,

Yingjie Du, Yishan Yao

и другие.

Journal of Psychopharmacology, Год журнала: 2024, Номер 38(5), С. 489 - 499

Опубликована: Апрель 28, 2024

Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether has antidepressant-like effects in mice potential are related promoted neuroplasticity. Methods: We first examined normal by forced swimming test chronic corticosterone (CORT)-exposed sucrose preference novelty-suppressed feeding test. Furthermore, explore role neuroplasticity mediating psilocybin, we measured structural neuroplasticity-associated protein levels prefrontal cortex (PFC) hippocampus. Results: observed that a single dose had both healthy CORT-exposed mice. Moreover, ameliorated CORT exposure-induced inhibition PFC hippocampus, including increasing (total number dendritic branches spine density), synaptic (p-GluA1, PSD95 synapsin-1) levels, BDNF-mTOR signalling pathway activation (BDNF, TrkB mTOR levels), promoting neurogenesis (number DCX-positive cells). Conclusions: Our results demonstrate elicits robust, which is accompanied promotion

Язык: Английский

Процитировано

16
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications DOI Creative Commons
Francesco Weiss, Anna Magnesa,

Matteo Gambini

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(2), С. 117 - 117

Опубликована: Янв. 25, 2025

Background: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still lively controversy in the medical community regards rationale of their employment, specifically indications potential dangers. Methods: A comprehensive literature search on “MEDLINE/PubMed” “Web Science” was performed from inception to 26 June 2024, cross-checking obtained references. We included all studies, i.e., both clinical preclinical, that supplied original data. Results: initially total 1083 entries, 813 MEDLINE/PubMed 270 Web Science. After duplicate elimination, 903 underwent systematic selection. Primary abstract screening yielded 572 candidates eligibility assessment excluded 331 entries formal grounds. Eligibility led exclusion 501 titles. Finally, 70 articles were this review. Discussion: Preclinical evidence genetic expression, histology behavioral studies soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, seems be inferentially agreement preclinical findings. it unclear whether “neuroplastic boost” induced by classic might dissociable psychodysleptic effects, thereby reducing psychopathological hazards implied these compounds. Moreover, fact so-called “relaxation priors” should unconditionally beneficial appears debatable, further research clarify possible contraindications psychedelic psychoplastogens within precision medicine perspective.

Язык: Английский

Процитировано

5
Psychedelics as Transformative Therapeutics DOI
Bryan L. Roth, Ryan H. Gumpper

American Journal of Psychiatry, Год журнала: 2023, Номер 180(5), С. 340 - 347

Опубликована: Май 1, 2023

Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most basic science has utilized these probes to interrogate various endogenous neurotransmitter systems-mainly serotonin 5-HT2A receptor. With renewed interest in utilizing and explosion clinical trials, psychedelics been purported treat many disorders, including depression, cluster headaches, migraines, anxiety, obsessive-compulsive disorder. It is therefore imperative understand biology pharmacology behind their therapeutic mechanisms well expose any potential pitfalls widespread use treatments. This review covers latest advances understanding biological mechanisms, newest efforts drug discovery, when it comes this class emerging therapeutics.

Язык: Английский

Процитировано

39